The adenosine A1 receptor antagonist BIIP 20 counteracts scopolamine-induced behavioral deficits in the passive avoidance task in the rat.
The present study investigated the effects of the putative adenosine A1 receptor antagonist BIIP 20 ((S)-(-)-8-(3-oxocyclopentyl)-1,3-dipropyl-7H-purine-2,6-dione) on counteracting scopolamine-induced behavioral deficits in the rat in the passive avoidance paradigm. A single oral application of BIIP 20 (1 and 3 mg/kg) 90 min before the rats received the noxious stimulus significantly attenuated the scopolamine-induced deficits observed during the retention trial of this task.
Pitsikas
N
N
Department of Biology, Boehringer Ingelheim Italia, S.p.A., Milan, Italy.
Borsini
F
F
D000284:Administration, Oral; D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects*; D004558:Electric Stimulation; D007274:Injections, Intraperitoneal; D008297:Male; D008568:Memory / Q000187:drug effects*; D018727:Muscarinic Antagonists / Q000008:administration & dosage / Q000633:toxicity*; D017288:Pain Threshold / Q000187:drug effects; D058915:Purinergic P1 Receptor Antagonists; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D012601:Scopolamine / Q000008:administration & dosage / Q000633:toxicity*; D014970:Xanthines / Q000008:administration & dosage / Q000494:pharmacology*
D018727:Muscarinic Antagonists; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; C080664:KFM 19; D012601:Scopolamine